MyAverix Finance MyAverix Finance

US

Ligand Pharms Glucagon (LGNXZ)

Ligand Pharms Glucagon (LGNXZ) is listed on US. As of 2026-03-30, reported P/E ratio is 18.00, net margin is 46.4%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-30

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for LGNXZ

P/E ratio
18.00
Gross profit (TTM)
$172.36M
Net margin
46.4%

Ligand Pharms Glucagon (LGNXZ) — FAQ

What is LGNXZ's P/E ratio?

The price-to-earnings (P/E) ratio for Ligand Pharms Glucagon (LGNXZ) is 18.00 (data as of 2026-03-30).

Does Ligand Pharms Glucagon pay a dividend?

Dividend yield is not available in the current snapshot for Ligand Pharms Glucagon (LGNXZ). Check the MyAverix Finance app for the latest dividend data.

What exchange is LGNXZ listed on?

LGNXZ is listed on US.

What is Ligand Pharms Glucagon's net margin?

Ligand Pharms Glucagon (LGNXZ) reports a net margin of 46.4% (data as of 2026-03-30).

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play